(2S)-2-Hydroxypropanoic acid - 1-cyclopropyl-3-{3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl}urea (1:1)(CAS: 896466-76-5)

This compound is subject to the REACH regulations in the EU, which require manufacturers and importers to register substances if they have a tonnage threshold of 1 ton per year. Additionally, it may fall under the GHS classification as a hazardous chemical due to its pharmacological activity. FDA and EPA regulations could also apply in the USA, requiring specific documentation and handling procedures to ensure safety and environmental protection.

Alternative reagents such as related compounds like morpholinyl derivatives or other substituted ureas can be used as synthetic alternatives. Isomers or analogs with similar pharmacological properties may also serve as viable alternatives depending on the specific requirements of the synthesis process.

The market for this compound is primarily driven by its application in pharmaceutical research, particularly in the development of antiviral and anticancer drugs. Research trends show increasing interest in exploring its potential for treating viral infections and cancers, with a focus on optimizing its efficacy and reducing side effects. Market trends indicate growing investment in clinical trials and preclinical studies.

Waste containing this compound should be collected in appropriate containers and disposed of through professional waste disposal services. Hazardous waste incineration is a common method for disposal, ensuring compliance with environmental protection regulations. Precautions include proper labeling, handling to prevent spills, and adherence to local and international waste management guidelines to minimize environmental impact.